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ABSTRACT 
Introduction: The rate of bacterial co-infection with SARS-CoV-2 is poorly defined. 
The decision to administer antibiotics early in the course of SARS-CoV-2 infection 
depends on the likelihood of bacterial co-infection. 
Methods: We performed a retrospective chart review of all patients admitted through the 
emergency department with confirmed SARS-CoV-2 infection over a 6 week period in a 
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large healthcare system in the United States. Blood and respiratory culture results were 
abstracted and adjudicated by multiple authors. The primary outcome was the rate of 
bacteremia. We secondarily looked to define clinical or laboratory features associated 
with bacteremia.  
Results: There were 542 patients admitted with confirmed SARS-CoV-2 infection, with 
an average age of 62.8 years. Of these, 395 had blood cultures performed upon 
admission, with 6 true positive results (1.1% of the total population). An additional 14 
patients had positive respiratory cultures treated as true pathogens in the first 72 hours. 
Low blood pressure and elevated white blood cell count, neutrophil count, blood urea 
nitrogen, and lactate were statistically significantly associated with bacteremia. Clinical 
outcomes were not statistically significantly different between patients with and without 
bacteremia. 
Conclusions: We found a low rate of bacteremia in patients admitted with confirmed 
SARS-CoV-2 infection. In hemodynamically stable patients, routine antibiotics may not 
be warranted in this population.  
INTRODUCTION 
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) global 
pandemic has already infected over 75 million individuals and caused more than a 
million deaths.1 The disease has overwhelmed health care systems and challenged 
clinicians’ ability to provide timely evidence-based care, especially to critically ill 
patients.2 The Surviving Sepsis Campaign (SSC) recently issued 54 statements regarding 
management of critically ill adults with COVID-19, the disease caused by SARS-CoV-2,3 










addressing topics such as fluid resuscitation, mechanical ventilation, steroids, and 
intravenous immunoglobulins. However, most of these recommendations are based on 
limited evidence due to the novelty of the disease.  
One clinical dilemma raised by the SSC is whether to use antibiotics in patients with 
COVID-19. Discerning concomitant bacterial sepsis or superinfection among patients 
with COVID-19 can be very difficult, given the similarity in symptoms (fever, cough, 
myalgias, etc).4 The uncertainty surrounding clinical management is reflected in data 
from Wuhan, where up to 53% of patients with non-severe disease and >90% of patients 
admitted to the hospital were given intravenous antibiotics.5-7 A systematic review of 76 
studies encompassing over 11,000 patients with COVID-19 found that 64% were treated 
with antibiotics. Data from other severe respiratory viruses suggest significant rates of 
bacterial co-infection. Research on the Middle East Respiratory Syndrome demonstrated 
an 18% bacterial co-infection rate in 330 patients in the ICU,8 while the reported bacterial 
co-infection rate in influenza ranges from 11% to 35%.9 Recent systematic reviews have 
reported bacterial co-infection rates of approximately 7% for hospitalized patients with 
COVID-19, but are based on a small number of studies, many of which do not discern 
between bacterial infections present on admission versus those acquired in the 
hospital.10,11 A large multicenter registry reported a 3.5% community-onset bacterial co-
infection with COVID-19,12 and despite frequent use of broad spectrum antibiotics, 
further data is urgently needed.13 Further, patients with suspected bacterial co-infection 
may have worse outcomes.14 The most current guidelines from the SSC recommend 
empiric antimicrobial treatment for mechanically ventilated patients, with early de-
 











escalation guided by microbiology and culture results; but acknowledge those 
recommendations are based on low-quality evidence.3 
This study aimed to define the rate of bacteremia or bacterial co-infection in admitted 
COVID-19 patients and to identify clinical or laboratory risk factors associated with 
bacteremia to help guide early antimicrobial use. 
METHODS 
This retrospective chart review was approved as exempt research by the local institutional 
review board. 
Patients and Settings 
The study took place across a large integrated health system that includes 14 hospitals 
across the state of Indiana. Annual emergency department (ED) volume across the 
hospitals ranges from approximately 6,000 to 90,000, and the system sees over 400,000 
combined ED patients annually. 
Included patients were adults aged ≥ 18 years, admitted to the hospital from the ED 
between March 1, 2020, and April 13, 2020, with a positive Polymerase Chain Reaction 
(PCR) test for SARS-CoV-2 within 3 days of admission. Patients with a PCR test 
obtained greater than 3 days after hospital admission were excluded because this is the 
earliest timeframe in which a positive test could be reasonably attributed to an infection 
occurring during the early part of the hospitalization, rather than being present prior to 
admission. No further exclusion criteria were applied. 
 











Data Collection  
Data was abstracted using a standardized form and was entered into REDCap,15 a secure 
data collection instrument. Extracted data included days from symptom onset to ED 
presentation, basic demographics (age and gender), comorbidities, ED vitals signs, 
laboratory values (culture results and chest imaging results), and level of care at the time 
of admission. Level of care was defined based on the computerized order entered by the 
admitting hospitalist team. Chest imaging results based on final radiologist interpretation 
were labeled as “clear,” “single lobe infiltrates,” “multi-lobar infiltrates,” or “clear x-ray 
with involvement on CT only.” Vital signs included initial and final ED blood pressure, 
heart rate, oxygen saturation, temperature, and respiratory rate. If an ambulatory oxygen 
saturation was documented in the electronic medical record (EMR), it was extracted and 
recorded separately. Comorbidities were based on chart review of the ED note, admission 
note, and any clinic or primary care notes available in the EMR. The presence or absence 
of the following comorbidities was recorded for each patient: smoking, obesity, 
hypertension, diabetes, hyperlipidemia, heart failure, previous ischemic heart disease, 
active cancer, dialysis dependent renal disease, chronic obstructive pulmonary disease 
(COPD), asthma, active cancer, current chemotherapy, HIV, history of organ 
transplantation, and current use of oral immunosuppressants.  
Outcomes 
The primary outcome was the rate of true positive blood cultures performed at admission 
(within 24 hours of hospital arrival) in patients who tested positive for COVID-19. All 
blood culture results were initially documented as negative, positive (any bacterial 
 











growth in any bottle), or not done. Since some positive blood cultures can be caused by 
skin contaminants not causing any infection, all positive cultures were adjudicated by 2 
authors as either true positive or contaminants. Criteria to determine “true positive” 
versus “contaminant” were predefined. Institutional protocol directs collection of 4 
bottles (2 from each of 2 different sites) when drawing blood cultures. Any case in which 
more than 2 of 4 bottles grew bacteria were considered true positives. Any patient with 
repeat blood cultures that were positive were considered true positive. Growth of bacteria 
outside of typical skin flora (such as staphylococcus or streptococcus) was generally 
considered true positive. If a positive in <3 of 4 bottles was noted to be a “probable 
contaminant” in the provider notes or infectious disease consultation notes, and if 
antibiotics were discontinued before 5 days of treatment, growth was classified as a false 
positive. In cases of disagreement, the discrepancy was resolved through discussion or 
adjudicated by a third author. Patients in whom no blood cultures were drawn within 72 
hours were classified as not bacteremic. Patients with positive culture results were thus 
divided into “true positive” bacteremia versus “contaminant.” We defined associations 
between clinical variables and true positive blood cultures and compared clinical 
outcomes between those with and without true positive blood cultures. 
We also assessed respiratory cultures drawn in the first 72 hours. Since it is more difficult 
to define a true positive respiratory culture versus contaminant or carrier state, all 
respiratory cultures with bacterial growth were considered true pathogens if the admitting 
team treated them as such, and incidental (not causing infection) if the care team noted 
the findings to be likely non-infectious and the patient was successfully treated without 
antibiotics.  
 











Urine cultures were not included in our analyses, since urinalysis can be performed with 
immediate results to guide antibiotic treatment related to urine infections, so initially 
“occult” urine infection is unlikely. Further, asymptomatic bacteriuria is common in 
some populations. 
Statistical Analysis  
Mean ages were compared using a two-sided t-test after a test for the ratio between the 
two standard deviations showed no significant difference. Categorical data were 
compared based on blood culture results with Fisher’s exact test and p-values were 
reported when statistically significant. Comparison of means was otherwise accomplished 
through an analysis of variance between groups if the concurrent Bartlett’s test for equal 
variances did not refute the validity of the comparison. P-values were not reported if 
Bartlett’s test demonstrated significant differences. All statistical analyses were 
performed using Stata/IC 16.1 (StataCorp LLC, College Station, Texas). 
RESULTS 
We identified 542 adults with a positive COVID-19 PCR test admitted during the study 
period, and all were included. Table 1 provides demographic information on the cohort. 
The average patient age was 62.8 years; 49.6% were male. Patients with bacteremia were 
older than those without (79.8 vs 62.6 years; p = 0.01) but were otherwise similar 
demographically and had similar comorbidities. Among all patients, 395 (73%) had blood 
cultures performed at admission. Of those, 42 demonstrated growth in any bottle, and 6 
demonstrated true positive blood cultures, representing 1.1% (95% CI = 0.4% to 2.3%) of 
the study population and 14% of all blood cultures with any bacterial growth. Table 2 
 











provides details on the 6 bacteremic patients. There were 12 positive blood cultures 
drawn after at least 24 hours in the hospital. Only one of the 12 was performed within 72 
hours of admission and was a contaminant.  
Respiratory cultures were performed on 80 patients in the first 24 hours of 
hospitalization, of which 16 reported any growth. Of those, 7 (5 staphylococcus aureus) 
were treated as true pathogens by the admitting teams. There were 12 patients with any 
growth on respiratory cultures between 24 and 72 hours, 8 of which were treated as true 
pathogens, for a total of 15 (2.8%, 95% CI = 1.6% to 4.5%) patients with any bacterial 
respiratory pathogen treated in the first 72 hours of admission. One patient had both a 
true positive blood culture and a true positive respiratory culture by our definitions, 
although the cultures were positive for different organisms. 
Table 3 displays the initial vital sign, laboratory, and radiographic data stratified by the 
presence or absence of early bacteremia. Although patients with bacteremia tended to 
have higher heart rate, higher respiratory rate, and lower oxygen saturation, the only vital 
sign differences reaching statistical significance were systolic and diastolic blood 
pressures, which were both lower in patients with bacteremia. Patients with bacteremia 
had significantly higher white blood cell counts (13.5 vs 7.3), neutrophil counts (12.4 vs 
5.7), and lactate (4.1 vs 1.6). C-reactive protein, and procalcitonin values were higher in 
patients with bacteremia, but these differences did not reach statistical significance. 
Table 4 displays vital sign, laboratory, and radiology findings among the 20 patients with 
any true positive bacterial culture (blood or respiratory) compared to those without any 
true positive bacterial culture. Vital sign findings were similar to the comparisons in table 
 











3, with lower blood pressure noted in patients with bacterial co-infection, but in the 
comparison including those with true positive respiratory cultures, co-infected patients 
were also had statistically significantly lower pulse oximetry readings. Lactate was no 
longer statistically significantly associated with true positive cultures when including 
blood and respiratory co-infections, but other laboratory associations were similar to 
those found in patients with bacteremia. 
Mortality for the entire cohort was 14.4%. None of the 6 patients with bacteremia died, 
but 3 of the 6 were intubated (compared to 29.7% of those without bacteremia). Intensive 
care admission was 15.9% without, and 50% with bacteremia. None of the differences in 
clinical outcomes reached statistical significance. Outcomes are presented in Table 5.  
DISCUSSION 
We found a low rate of early bacteremia or bacterial respiratory co-infection among 
patients admitted to the hospital from the ED with confirmed COVID-19 infection. The 
small number of bacteremic patients precluded robust evaluation of associations, but our 
results suggest that older age, lower blood pressure, and certain laboratory abnormalities 
are associated with an increased risk of bacteremia. In addition to bacteremia, there were 
additional patients who were treated for positive respiratory cultures, although this 
number was also small. Combining all bacteremic patients and those with positive 
respiratory cultures within 72 hours of admission, 20/542 (3.7%; 95% CI = 2.3% to 
5.6%) of all patients had a documented bacterial co-infection. 
The initial treatment of patients with COVID-19 is complicated by several factors, 
including lack of proven therapies, delays in COVID-19 test results, and clinical 
 











presentations that often have significant overlap with bacterial pneumonia or sepsis.4 One 
of the initial treatment decisions for patients admitted with presumed or confirmed 
COVID-19 is whether or not to cover with antibiotics for bacterial co-infection, or 
bacterial infection masquerading as COVID-19. Current guidelines reflect the uncertainty 
in the evidence. The SSC recommends antibiotics in mechanically ventilated patients, but 
rates this as a weak recommendation based on low quality of evidence.3 The National 
Institute for Health and Care Exchange (NICE) guidelines state: “If there is confidence 
that the clinical features are typical for COVID-19, it is reasonable not to start empirical 
antibiotics,” but generally recommend antibiotics for those with sepsis criteria or those in 
whom bacterial infection is suspected.16 Our findings imply that older patients, patients 
with comorbidities, and those with hypotension are likely higher risk for bacterial co-
infection and these factors may reasonably lower a clinician’s threshold to initiate 
antibiotic therapy for patients admitted to the hospital from the ED with a COVID-like 
illness.  
Additionally, the current study adds to previous work to determine the rate of bacterial 
co-infection in patients with COVID-19. Recent systematic reviews have found bacterial 
co-infection rates with COVID-19 of 6.9% and 7.0% overall.10,11 One review noted that 
the rate of co-infection at presentation was 3.5%, with the remainder attributed to hospital 
acquired infections.10 Our rate of 3.7% with evidence of bacteremia or pulmonary 
infection identified within 72 hours of admission further corroborates those previous 
findings, as well as those of another multicenter registry.17  
While procalcitonin has shown promise in helping differentiate bacterial infections from 
other types of infection or illness,18,19 data related specifically to COVID-19 is sparse,20 
 











and our results did not support a clear association between elevated procalcitonin and 
bacterial co-infection. While we found some association between certain laboratory 
values and bacterial co-infection, we had too few cases of co-infection to make 
recommendations regarding how to interpret these laboratory values in patients with 
COVID-19.  
LIMITATIONS 
There are several important limitations to this study. First, only patients with PCR 
confirmed COVID-19 were included. The overall rate of bacteremia or bacterial infection 
may be different in “suspected COVID-19” patients than in those who have a confirmed 
diagnosis. Since PCR results may not be available early in the course of a patient 
admitted for suspected COVID-19, our results cannot suggest that it is safe to withhold 
antibiotics from a suspected COVID-19 patient until the PCR result is positive. Once the 
patient is confirmed to have COVID-19 however, our findings suggest that the rate of 
concurrent bacterial infection is likely quite low.  
We prioritized bacteremia as our primary outcome because of the difficulty in defining a 
true positive respiratory culture. We found that an additional 2.6% of patients were 
treated for a bacterial pulmonary pathogen identified within the first 72 hours of 
admission. While these patients were treated with antibiotics at our institution, it is 
unclear whether these cultures represented true bacterial pathogens or incidental bacterial 
flora.  
We found a very small number of bacteremic patients. The small number of true positives 
also limited our ability to find statistical associations between patient characteristics and 
bacteremia, and there were far too few cases to try to derive a decision instrument.  
 











Although we set objective criteria for true positive cultures vs. contaminants, there is no 
universally accepted way to adjudicate such cases, and this process may lead to errors 
resulting in either over- or under-estimation of bacterial infections.  
Seasonal variations in bacterial sepsis and influenza may also impact the applicability of 
these results to different times of the year. Lastly, although the data was taken from 14 
different hospitals, they all operate in the same state under the same healthcare system, so 
our results may not be widely applicable to other healthcare systems or settings. 
CONCLUSIONS 
We found a low rate of bacteremia or bacterial pulmonary infection among patients 
admitted to the hospital with confirmed COVID-19 infection. Combined with other 
studies, our results suggest that physicians may consider treating hemodynamically stable 
patients with confirmed COVID-19 and without high clinical suspicion for bacterial co-
infection without routine antibiotics. 
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Table 1: Patient Demographics and Comorbidities  
Mean Age (sd*) 62.8 (16.5) 
Female – no. (%) 273 (50.4) 
Tobacco Use – no. 
(%) 
43 (8) 
Obesity 211 (39.0) 
Diabetes 218 (40.3) 
Hyperlipidemia 281 (51.7) 
Hypertension 368 (67.5) 
COPD 68 (12.5) 
Asthma 57 (10.4) 
Organ Transplant 6 (1.1) 
HIV 6 (1.1) 
*sd = standard deviation 
  
 











Table 2: Characteristics of Patients with True Positive Blood Culture Results 
Patient Blood Culture Findings Treatment Course Disposition 
1 Aerobic and anaerobic bottles growing 
Coagulase negative staphylococcus. Positive 
for Methicillin-resistance Staphylococcus 
epidermidis. Repeat blood culture- aerobic 
bottle grew coagulase negative staphylococcus. 
Started on Meropenem and 
Vancomycin and narrowed 
to vancomycin after 2 days 
for a total of 5 days prior to 




2 Aerobic bottle growing Enterococcus faecalis 
and aerococcus species. Anaerobic bottle 
growing Globicatella. Repeat blood cultures 
negative. 
Treated with IV 
Vancomycin for 10 days 
and Cefepime for 6 days.  
Discharged 
home 
3 Anaerobic bottle growing Enterococcus 
faecalis. 
Treated with IV ceftriaxone 
and doxycycline for first 2 
days. De-escalated to IV 
ampicillin for a 8 days. 
Discharged 
home 
4 Aerobic and anaerobic bottles growing 
Methicillin-resistant Staphylococcus 
epidermidis. Aerobic bottles growing 
Corynebacterium striatum. Repeat blood 
cultures (2/2) growing Staphylococcus 
epidermidis. 




5 Aerobic bottle (2/2) growing Coagulase 
negative Staphylococcus (Staph pettenkoferi). 




6 Aerobic bottle growing Acinetobacter 
radioresistense. Urine culture positive for 
Klebsiella and Escherichia coli. 
Received 10 days of 
cefepime for both blood 


















Table 3: Characteristics of Initial Presentation By Blood Culture Status 
 Patients without 
True Positive Blood 
Cultures (n = 536) 
Patients with True 
Positive Blood 
Cultures (n = 6) 
P 
Value 
 Mean (sd*)  
Days since symptom onset 7.1 (5.4) 4.3 (5.5) 0.21 
Initial vital signs and 
laboratory values 
   
Temperature (Celsius) 37.6 (1.1) 37.9 (1.7) 0.39 
Heart rate 97.9 (20.7) 111.5 (27.7) 0.11 
Respiratory rate 22.6 (6.7) 26.8 (10.8) 0.13 
Systolic blood pressure 135.0 (22.7) 104.2 (22.9) 0.001 
Diastolic blood 
pressure 
77.9 (17.2) 63.7 (8.4) 0.043 
Pulse oximetry reading 91.8 (8.0) 86.2 (14.4) 0.09 
White Blood Cell 
Count 
7.3 (3.5) 13.5 (4.0) < 0.001 
Absolute Neutrophil 
Count 
5.7 (3.2) 12.4 (6.2) <0.001 
Lactate 1.6 (1.3) 4.1 (1.9) < 0.001 
CRP 13.4 (18.9) 15.7 (8.6) 0.81 
 










 Procalcitonin 1.4 (9.8) 3.2 (5.3) 0.69  
Radiology Results  No. (%) NS** 
No radiographic 
findings 
61 (11.6) 1 (16.7)  
Single lobe 
involvement 
55 (10.5) 1 (16.7)  
Multilobe involvement 387 (73.9) 4 (66.7)  
Positive CT without 
positive radiograph 
21 (4.0) 0 (0)  
 
*sd = Standard deviation 
** Not statistically significant 
Table 4: Characteristics of Initial Presentation By Blood or Respiratory Culture 
Status 
 Patients without 
True Positive Blood 
or Respiratory 
Cultures (n = 522) 
Patients with True 
Positive Blood or 
Respiratory Cultures 
(n = 20) 
P 
Value 
 Mean (sd*)  
Days since symptom onset 7 (5) 6 (7) NS** 
Initial vital signs and    
 












Temperature (Celsius) 37.6 (1.0) 37.5 (1.8) NS 
Heart rate 98 (21) 104 (23) NS 
Respiratory rate 23 (7) 25 (11) NS 
Systolic blood pressure 135 (23) 124 (30) 0.042 
Diastolic blood 
pressure 
78 (17) 69 (17) 0.021 
Pulse oximetry reading 92 (7) 79 (18) 0.0039 
White Blood Cell 
Count 
7.3 (3.4) 9.7 (4.7) 0.033 
Absolute Neutrophil 
Count 
5.6 (3.2) 8.5 (5.3) 0.027 
Lactate 1.6 (1.3) 2.2 (1.9) NS 
CRP 13.1 (19.0) 21.1 (12.7) NS 
Procalcitonin 1.2 (9.1) 7.0 (18.4) NS 
 
Radiology Results  No. (%)  
No radiographic 
findings 
61 (12) 1 (5) NS 
 










 Single lobe involvement 55 (11) 1 (5) 
Multilobe involvement 373 (73) 18 (90) 
Positive CT without 
positive radiograph 
21 (4) 0 (0) 
*sd = Standard deviation 
** Not statistically significant 
Table 5: Comparison of Outcomes by Blood Culture Status 
 Patients without True 
Positive Blood Cultures 
Patients with True 
Positive Blood 
Cultures 
 No. (%)  
Admitted to ICU 83 (15.9) 3 (50.0) 
Started on dialysis prior to 
discharge 
24 (4.5) 0 (0) 
Intubated prior to discharge 159 (29.7) 3 (50.0) 
Died before discharge 78 (14.6) 0 (0) 
*All three intubations in the true positive group occurred within 24 hours. 
** No findings were statistically significant by Fisher’s exact test. 
 
